SOPHiA GENETICS SA Hits New 52-Week High of USD 8.68

SOPHiA GENETICS SA has reached a significant milestone by hitting a new 52-week high of USD 8.68 on August 21, 2026. This achievement marks a notable increase from its 52-week low of USD 3.10, reflecting a robust one-year performance of 80.21%, significantly outperforming the S&P 500, which recorded a gain of 20.47% during the same period. As a microcap company in the Software Products industry, SOPHiA GENETICS SA has a market capitalization of USD 337 million. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -159.46%. The stock currently has a price-to-book ratio of 7.14, indicating a premium valuation relative to its book value. Investors may find the company's financial metrics noteworthy, particularly its debt-to-equity ratio of -0.42, which suggests a unique capital structure. Overall, SOPHiA GENETICS SA's recent performance highlights its position within the software sector and its potential for continued attention in the market.